Limits...
Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous.

Dai Y, Wu Z, Wang F, Zhang Z, Yu M - Biomed Res Int (2014)

Bottom Line: The significantly higher levels of CCL4 and CCL11 in PDR contradict the results of previous reports.Based on Spearman's nonparametric test, moderate-to-strong correlations were found between VEGF and other mediators.Our results indicate that these chemokines and growth factors could be candidates for research into targeted therapies applied either singly or in combination with anti-VEGF drugs for the treatment of PDR.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Wuxi No. 2 Hospital, Nanjing Medical University, Zhongshan 68, Wuxi 214002, China.

ABSTRACT
Associations were investigated between levels of chemokines and growth factors in the vitreous and proliferative diabetic retinopathy (PDR). Enrolled were 58 patients (58 eyes) requiring pars plana vitrectomy (PPV), with PDR (n=32, none with traction retinal detachment) or not (non-PDR). In the latter, 16 had macular hole (MH) and 10 had epiretinal membrane (ERM). With a multiplex bead immunoassay, levels of 11 chemokines and growth factors were measured from the undiluted vitreous sample from each patient. In the non-PDR eyes, the levels of the 11 chemokines and growth factors tested were similar between patients with MH and those with ERM. However, the levels of all 11 were significantly higher in the PDR eyes relative to the non-PDR; CCL17, CCL19, and TGFβ3 were markedly upregulated and have not been investigated in PDR previously. The significantly higher levels of CCL4 and CCL11 in PDR contradict the results of previous reports. Based on Spearman's nonparametric test, moderate-to-strong correlations were found between VEGF and other mediators. Our results indicate that these chemokines and growth factors could be candidates for research into targeted therapies applied either singly or in combination with anti-VEGF drugs for the treatment of PDR.

Show MeSH

Related in: MedlinePlus

Correction analysis between VEGF and other mediators in PDR vitreous. Based on Spearman's analysis, moderate-to-strong corrections were observed between VEGF and CCL2, CCL11, CCL17, CCL19, CXCL9, TGFβ1, TGFβ2, and TGFβ3.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4226181&req=5

fig2: Correction analysis between VEGF and other mediators in PDR vitreous. Based on Spearman's analysis, moderate-to-strong corrections were observed between VEGF and CCL2, CCL11, CCL17, CCL19, CXCL9, TGFβ1, TGFβ2, and TGFβ3.

Mentions: In PDR eyes, strongly positive correlations were noted between VEGF and CCL17 (r = 0.616, P < 0.001) and between VEGF and TGFβ1 (r = 0.635, P < 0.001). In PDR vitreous, moderate but significant associations were found between VEGF and CCL2 (r = 0.593, P < 0.001), CCL11 (r = 0.541, P = 0.001), CCL19 (r = 0.572, P = 0.001), CXCL9 (r = 0.425, P = 0.015), TGFβ2 (r = 0.537, P = 0.002), and TGFβ3 (r = 0.500, P = 0.004). The correlations of vitreous obtained from PDR patients were exhibited in Figure 2.


Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous.

Dai Y, Wu Z, Wang F, Zhang Z, Yu M - Biomed Res Int (2014)

Correction analysis between VEGF and other mediators in PDR vitreous. Based on Spearman's analysis, moderate-to-strong corrections were observed between VEGF and CCL2, CCL11, CCL17, CCL19, CXCL9, TGFβ1, TGFβ2, and TGFβ3.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4226181&req=5

fig2: Correction analysis between VEGF and other mediators in PDR vitreous. Based on Spearman's analysis, moderate-to-strong corrections were observed between VEGF and CCL2, CCL11, CCL17, CCL19, CXCL9, TGFβ1, TGFβ2, and TGFβ3.
Mentions: In PDR eyes, strongly positive correlations were noted between VEGF and CCL17 (r = 0.616, P < 0.001) and between VEGF and TGFβ1 (r = 0.635, P < 0.001). In PDR vitreous, moderate but significant associations were found between VEGF and CCL2 (r = 0.593, P < 0.001), CCL11 (r = 0.541, P = 0.001), CCL19 (r = 0.572, P = 0.001), CXCL9 (r = 0.425, P = 0.015), TGFβ2 (r = 0.537, P = 0.002), and TGFβ3 (r = 0.500, P = 0.004). The correlations of vitreous obtained from PDR patients were exhibited in Figure 2.

Bottom Line: The significantly higher levels of CCL4 and CCL11 in PDR contradict the results of previous reports.Based on Spearman's nonparametric test, moderate-to-strong correlations were found between VEGF and other mediators.Our results indicate that these chemokines and growth factors could be candidates for research into targeted therapies applied either singly or in combination with anti-VEGF drugs for the treatment of PDR.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Wuxi No. 2 Hospital, Nanjing Medical University, Zhongshan 68, Wuxi 214002, China.

ABSTRACT
Associations were investigated between levels of chemokines and growth factors in the vitreous and proliferative diabetic retinopathy (PDR). Enrolled were 58 patients (58 eyes) requiring pars plana vitrectomy (PPV), with PDR (n=32, none with traction retinal detachment) or not (non-PDR). In the latter, 16 had macular hole (MH) and 10 had epiretinal membrane (ERM). With a multiplex bead immunoassay, levels of 11 chemokines and growth factors were measured from the undiluted vitreous sample from each patient. In the non-PDR eyes, the levels of the 11 chemokines and growth factors tested were similar between patients with MH and those with ERM. However, the levels of all 11 were significantly higher in the PDR eyes relative to the non-PDR; CCL17, CCL19, and TGFβ3 were markedly upregulated and have not been investigated in PDR previously. The significantly higher levels of CCL4 and CCL11 in PDR contradict the results of previous reports. Based on Spearman's nonparametric test, moderate-to-strong correlations were found between VEGF and other mediators. Our results indicate that these chemokines and growth factors could be candidates for research into targeted therapies applied either singly or in combination with anti-VEGF drugs for the treatment of PDR.

Show MeSH
Related in: MedlinePlus